The Impact of geographic variations in treatment on outcomes in ovarian cancer

International Journal of Gynecological Cancer

Volumn 23, Issue 2, 2013, Pages 282-287

  Dehaeck, Ulrike ^a   McGahan, Colleen E ^a   Santos, Jennifer L ^a   Carey, Mark S ^a   Swenerton, Kenneth D ^a   Kwon, Janice S ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Combination chemotherapy; Health authority region; Optimal debulking; Outcomes; Ovarian cancer; Treatment

Indexed keywords

CARBOPLATIN;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL GEOGRAPHY; MORTALITY; OVARY CARCINOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRITISH COLUMBIA; COHORT STUDIES; FEMALE; GEOGRAPHY; GYNECOLOGIC SURGICAL PROCEDURES; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84876264490     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31827b87b1     Document Type: Article

References (19)

1. British Columbia Cancer Agency. http://www.bccancer.bc.ca. Cancer Statistics. Ovarian Cancer. Accessed December 2011.
2. Chan JK, Kapp DS, Shin JY, et al. Influence of the gynecologic oncologist on the survival of ovarian cancer patients. Obstet Gynecol. 2007;109:1342-1350.
3. Vernoij F, Heintz P, Witteveen E, et al. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospital: A systematic review. Gynecol Oncol. 2007;105:801-812.
4. Engelen MJA, Kos HE, Wilemse PHB, et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer. 2006;106:589-598.
5. Winter WE, Maxwell GL, Chunqiao T, et al. Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:3621-3627.
6. Elattar A, Bryant A, Winter-Roach BA, et al. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Sys Rev. 2011;10:CD007565.
7. Carney ME, Lancaster JM, Ford C, et al. A population based study of patterns of care for ovarian cancer: Who is seen by a gynecologic oncologist and who is not? Gynecol Oncol. 2002;84:36-42.
8. du Bois A, Rochon J, Pfisterer J, et al. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: A systematic review. Gynecol Oncol. 2009;111;422-436.
9. Vernooij F, Heintz AP, Coebergh JW, et al. Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the Netherlands. Gynecol Oncol. 2009;112: 455-461.
10. Everett EN, Heuser CC, Pastore LM, et al. Predictors of suboptimal surgical cytoreduction in women treated with initial cytoreductive surgery for advanced stage epithelial ovarian cancer. Am J Obstet Gynecol. 2005;193:568-574.
11. Dowdy SC, Mullany SA, Brandt KR, et al. The utility of tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. Cancer. 2004;101:346-352.
12. Gemer O, Segal S, Kopmar A. Preoperative CA-125 level as a predictor of non optimal cytoreduction of advanced epithelial ovarian cancer. Acta Obstet Gynecol Scand. 2001;80:583-585.
13. National Cancer Intelligence Network. http://www.ncin.org.uk/ publications/data-briefings/major-resection.aspx NHS treated cancer patients receiving major resections-NCIN data briefing. Accessed August 2012.
14. British Columbia Cancer Agency. http://www.bccancer .bc.ca/HPI/ ChemotherapyProtocols/Gynecology/default .htm#ovarian Chemotherapy Protocols. Gynecology. Accessed January 2012.
15. National Comprehensive Cancer Network. http://www.nccn.org/professionals/ physician-gls/f-guidelines.asp#ovarian. NCCN Guidelines, Ovarian Cancer. Accessed January 2012.
16. The International Collaborative Ovarian Cancer Neoplasm (ICON) Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial. Lancet. 2002;360:505-515.
17. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-953.
18. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24:4699-4707.
19. Bookman MA. GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel and carboplatin vs combinations with gemcitabine, PEG-lipososomal doxorubicin, or topotecan in patients with advanced-stage epithelial ovarian or primary peritoneal carcinoma. J Clin Oncol. 2006;24:5002.